Recombinant human immunodeficiency virus-1 transactivator of transcription 1-86 allosterically modulates dopamine transporter activity

Synapse

Volumn 65, Issue 11, 2011, Pages 1251-1254

  Zhu, Jun ^a   Ananthan, Subramaniam ^b   MacTutus, Charles F ^a   Booze, Rosemarie M ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

Allosteric modulation; Cocaine; Dopamine transporter; HIV 1 tat; Uptake

Indexed keywords

COCAINE; DOPAMINE TRANSPORTER; INDATRALINE; N (2,2 DIPHENYLETHYL) 2 PHENYL 4 QUINAZOLINAMINE; QUINAZOLINE DERIVATIVE; RECOMBINANT HUMAN IMMUNODEFICIENCY VIRUS 1 TRANSACTIVATOR OF TRANSCRIPTION[1-86]; SORI 20040; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; DISEASE PREDISPOSITION; DOPAMINE UPTAKE; DRUG ABUSE; DRUG ACTIVITY; HIV ASSOCIATED DEMENTIA; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SPRAGUE DAWLEY RAT;

ALLOSTERIC REGULATION; ANIMALS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HIV-1; HUMANS; MALE; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 80052372068     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20949     Document Type: Article

References (14)

1. Chang L, Wang GJ, Volkow ND, Ernst T, Telang F, Logan J, Fowler JS. 2008. Decreased brain dopamine transporters are related to cognitive deficits in HIV patients with or without cocaine abuse. Neuroimage 42: 869-878.
2. Del Valle L, Croul S, Morgello S, Amini S, Rappaport J, Khalili K. 2000. Detection of HIV-1 Tat and JCV capsid protein. VP1, in AIDS brain with progressive multifocal leukoencephalopathy. J Neurovirol 6: 221-228.
3. Ferris MJ, Mactutus CF, Booze RM. 2008. Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: Current status of dopamine system vulnerability in NeuroAIDS. Neurosci Biobehav Rev 32: 883-909.
4. 1-72 alters acute and sensitized responses to cocaine. Pharmacol Biochem Behav 90: 723-729.
5. Hudson LG, Gale JM, Padilla RS, Pickett G, Alexander BE, Wang J, Kusewitt DF. 2010. Microarray analysis of cutaneous squamous cell carcinomas reveals enhanced expression of epidermal differentiation complex genes. Mol Carcinog 49: 619-629.
6. Nandi A, Dersch CM, Kulshrestha M, Ananthan S, Rothman RB. 2004. Identification and characterization of a novel allosteric modulator (SoRI-6238) of the serotonin transporter. Synapse 53: 176-183.
7. Nath A. 2010. Human immunodeficiency virus-associated neurocognitive disorder: Pathophysiology in relation to drug addiction. Ann N Y Acad Sci 1187: 122-128.
8. Pariser JJ, Partilla JS, Dersch CM, Ananthan S, Rothman RB. 2008. Studies of the biogenic amine transporters. 12. Identification of novel partial inhibitors of amphetamine-induced dopamine release. J Pharmacol Exp Ther 326: 286-295.
9. 3H]GBR 12, 935 binding. Mol Pharmacol 45: 125-135.
10. 3H]WIN 35, 428 binding to the dopamine uptake carrier. II. Effect of membrane fractionation procedure and freezing. J Neurosci Methods 51: 31-38.
11. Walker QD, Morris SE, Arrant AE, Nagel JM, Parylak S, Zhou G, Caster JM, Kuhn CM. 2010. Dopamine uptake inhibitors but not dopamine releasers induce greater increases in motor behavior and extracellular dopamine in adolescent rats than in adult male rats. J Pharmacol Exp Ther 335: 124-132.
12. Wallace DR, Dodson S, Nath A, Booze RM. 2006. Estrogen attenuates gp120- and tat1-72-induced oxidative stress and prevents loss of dopamine transporter function. Synapse 59: 51-60.
13. Wang GJ, Chang L, Volkow ND, Telang F, Logan J, Ernst T, Fowler JS. 2004. Decreased brain dopaminergic transporters in HIV-associated dementia patients. Brain 127: 2452-2458.
14. 3H]2beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane (WIN 35, 428) binding in rat striatal synaptosomes. J Pharmacol Exp Ther 329: 1071-1083.